Acenocoumarol, risk assessment tool, Bleeding risk, clotting risks.


Objective: To develop a statistical predictive model to ensure the safest use of oral anticoagulant (Acenocoumarol) therapy.

Methods: It is a retrospective observational single-center study done at PSG Hospitals in Coimbatore, Tamilnadu, India. The data were collected from 2019 to 2020 from Hospital Information System (HIS). The statistical analysis was done using Chi-square and Multinomial logistic regression.

Results: The study includes 82 patients who were treated with Acenocoumarol. The results were calculated using a student t-test and the P-value was<0.0001, which is significant as it is less than 0.05, and the prediction tool is developed by using Multinomial Logistic Regression.

Conclusion: The Risk Assessment tool was developed. As the sample size increases, the accuracy of predictability also increases. So further validation of the tool is required for more accuracy and the data input should also be increased.


Download data is not yet available.


Barcellona D, Vannini ML, Fenu L, Balestrieri C, Marongiu F. Warfarin or acenocoumarol: which is better in the management of oral anticoagulants? Thromb Haemost. 1998 Dec;80(6):899-902. PMID: 9869157.

Hirsh J. Oral anticoagulant drugs. N Engl J Med. 1991 Jun 27;324(26):1865-75. doi: 10.1056/NEJM199106273242606. PMID: 1801769.

Fihn SD, Callahan CM, Martin DC, McDonell MB, Henikoff JG, White RH. The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics. Ann Intern Med. 1996 Jun 1;124(11):970-9. DOI: 10.7326/0003-4819-124-11-199606010-00004. PMID: 8624064.

Poli D, Antonucci E, Testa S, Tosetto A, Ageno W, Palareti G; Italian Federation of Anticoagulation Clinics. Bleeding risk in very old patients on vitamin K antagonist treatment: results of a prospective collaborative study on elderly patients followed by Italian Centres for Anticoagulation. Circulation. 2011 Aug 16;124(7):824-9. doi: 10.1161/CIRCULATIONAHA.110.007864. Epub 2011 Aug 1. PMID: 21810658.

Palareti G, Cosmi B. Bleeding with anticoagulation therapy - who is at risk, and how best to identify such patients. Thromb Haemost. 2009 Aug;102(2):268-78. DOI: 10.1160/TH08-11-0730. PMID: 19652877.

Hilkens NA, Algra A, Greving JP. Prediction models for intracranial hemorrhage or major bleeding in patients on antiplatelet therapy: a systematic review and external validation study. J Thromb Haemost. 2016 Jan;14(1):167-74. DOI: 10.1111/jth.13196. Epub 2016 Jan 4. PMID: 26563743.

Selak V, Jackson R, Poppe K, Wu B, Harwood M, Grey C, Pylypchuk R, Mehta S, Kerr A, Wells S. Predicting Bleeding Risk to Guide Aspirin Use for the Primary Prevention of Cardiovascular Disease: A Cohort Study. Ann Intern Med. 2019 Mar 19;170(6):357-368. DOI: 10.7326/M18-2808. Epub 2019 Feb 26. PMID: 30802900.

Landefeld CS, Beyth RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med. 1993 Sep;95(3):315-28. DOI: 10.1016/0002-9343(93)90285-w. PMID: 8368229.

Yeh RW, Secemsky EA, Kereiakes DJ, Normand SL, Gershlick AH, Cohen DJ, Spertus JA, Steg PG, Cutlip DE, Rinaldi MJ, Camenzind E, Wijns W, Apruzzese PK, Song Y, Massaro JM, Mauri L; DAPT Study Investigators. Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention. JAMA. 2016 Apr 26;315(16):1735-49. doi: 10.1001/jama.2016.3775. Erratum in: JAMA. 2016 Jul 19;316(3):350. Erratum in: JAMA. 2016 Jul 19;316(3):350. PMID: 27022822; PMCID: PMC5408574.

Burgess S, Crown N, Louzada ML, Dresser G, Kim RB, Lazo-Langner A. Clinical performance of bleeding risk scores for predicting major and clinically relevant non-major bleeding events in patients receiving warfarin. J Thromb Haemost. 2013 Sep;11(9):1647-54. DOI: 10.1111/jth.12352. PMID: 23848301.

Froom P, Miron E, Barak M. Oral anticoagulants in the elderly. Br J Haematol. 2003 Feb;120(3):526-8. doi: 10.1046/j.1365-2141.2003.04110.x. PMID: 12580973.

Klok FA, Hösel V, Clemens A, Yollo WD, Tilke C, Schulman S, Lankeit M, Konstantinides SV. Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment. Eur Respir J. 2016 Nov;48(5):1369-1376. DOI: 10.1183/13993003.00280-2016. Epub 2016 Jul 28. PMID: 27471209.

van der Meer FJ, Rosendaal FR, Vandenbroucke JP, Briët E. Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. Arch Intern Med. 1993 Jul 12;153(13):1557-62. DOI: 10.1001/archinte.153.13.1557. PMID: 8323419.

Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb;141(2 Suppl):e44S-e88S. DOI: 10.1378/chest.11-2292. PMID: 22315269; PMCID: PMC3278051.

Claxton JS, MacLehose RF, Lutsey PL, Norby FL, Chen LY, O'Neal WT, Chamberlain AM, Bengtson LGS, Alonso A. A new model to predict major bleeding in patients with atrial fibrillation using warfarin or direct oral anticoagulants. PLoS One. 2018 Sep 10;13(9):e0203599. DOI: 10.1371/journal.pone.0203599. PMID: 30199542; PMCID: PMC6130859.

Beshir SA, Aziz Z, Yap LB, Chee KH, Lo YL. Evaluation of the predictive performance of bleeding risk scores in patients with non-valvular atrial fibrillation on oral anticoagulants. J Clin Pharm Ther. 2018 Apr;43(2):209-219. DOI: 10.1111/jcpt.12634. Epub 2017 Oct 13. PMID: 29030869.

Asiimwe IG, Waitt C, Sekaggya-Wiltshire C, Hutchinson C, Okello E, Zhang EJ, Semakula JR, Mouton JP, Cohen K, Blockman M, Lamorde M, Jorgensen AL, Pirmohamed M. Developing and Validating a Clinical Warfarin Dose-Initiation Model for Black-African Patients in South Africa and Uganda. Clin Pharmacol Ther. 2021 Jun;109(6):1564-1574. DOI: 10.1002/cpt.2128. Epub 2020 Dec 28. Erratum in: Clin Pharmacol Ther. 2021 Aug 16: PMID: 33280090.

Nielsen PB. Tooling in oral anticoagulation treatment. Medical Informatics Group. Department of Health Science and Technology.2010 August;01-34.

Palareti G, Leali N, Cocheri S, Poggi M, Manotti C, D'Angelo A, Pengo V, Erba N, Moia M, Ciavarella N, Devoto G, Berrettini M, Musolesi S. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet. 1996 Aug 17;348(9025):423-8. DOI: 10.1016/s0140-6736(96)01109-9. PMID: 8709780.

Trailokya A, Hiremath JS, Sawhney J, Mishra YK, Kanhere V, Srinivasa R, Tiwaskar M. Acenocoumarol: A Review of Anticoagulant Efficacy and Safety. J Assoc Physicians India. 2016 Feb;64(2):88-93. PMID: 27730796.

Rathore SS, Agarwal SK, Pande S, Singh SK, Mittal T, Mittal B. Therapeutic dosing of acenocoumarol: proposal of a population-specific pharmacogenetic dosing algorithm and its validation in north Indians. PLoS One. 2012;7(5):e37844. DOI: 10.1371/journal.pone.0037844. Epub 2012 May 22. PMID: 22629463; PMCID: PMC3358293.

. van der Meer FJ, Rosendaal FR, Vandenbroucke JP, Briët E. Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. Arch Intern Med. 1993 Jul 12;153(13):1557-62. DOI: 10.1001/archinte.153.13.1557. PMID: 8323419.

Rivera-Caravaca JM, Marín F, Esteve-Pastor MA, Valdés M, Vicente V, Roldán V, Lip GYH. Antiplatelet therapy combined with acenocoumarol in relation to major bleeding, ischaemic stroke, and mortality. Int J Clin Pract. 2018 Mar;72(3):e13069. DOI: 10.1111/ijcp.13069. Epub 2018 Feb 12. PMID: 29436121.

Cesar JM, García-Avello A, Navarro JL, Herraez MV. Aging and oral anticoagulant therapy using acenocoumarol. Blood Coagul Fibrinolysis. 2004 Oct;15(8):673-6. DOI: 10.1097/00001721-200412000-00007. PMID: 15613922.

Kooistra HA, Calf AH, Piersma-Wichers M, Kluin-Nelemans HC, Izaks GJ, Veeger NJ, Meijer K. Risk of Bleeding and Thrombosis in Patients 70 Years or Older Using Vitamin K Antagonists. JAMA Intern Med. 2016 Aug 1;176(8):1176-83. DOI: 10.1001/jamainternmed.2016.3057. PMID: 27379731.

Teichert M, van Noord C, Uitterlinden AG, Hofman A, Buhre PN, De Smet PA, Straus S, Stricker BH, Visser LE. Proton pump inhibitors and the risk of over anticoagulation during acenocoumarol maintenance treatment. Br J Haematol. 2011 May;153(3):379-85. doi: 10.1111/j.1365-2141.2011.08633.x. Epub 2011 Mar 21. PMID: 21418179.

Belkacemi M, Merad Y, Berber A. Frequency of bleeding complications in Algerian patients treated with the vitamin K antagonist acenocoumarol and associated factors. International Journal of Basic & Clinical Pharmacology. 2021 Nov;10(11):1.



How to Cite

SIVAKUMAR, V., S. S., M. A., G. KUMAR N., and A. C. P. “DEVELOPMENT OF A PREDICTION TOOL FOR THE ASSESSMENT OF RISKS ASSOCIATED WITH ACENOCOUMAROL”. International Journal of Pharmacy and Pharmaceutical Sciences, vol. 15, no. 1, Jan. 2023, pp. 33-36, doi:10.22159/ijpps.2023v15i1.46434.



Original Article(s)